Infineis wants to simplify intracranial surgery and fight against medical deserts

Infineis intends to reinvent stereotaxy, this tracking technique used in neurosurgery to reach specific areas of the brain. Combined with a frame fixed to the patient’s skull, called a stereotactic frame, it makes it possible to define the position and volume of a tumour, for example, and to guide the surgeon’s hand in the brain. A complex intervention that requires “highly trained staff, intraoperative imaging, registration x-rays, C-arm installation and long recovery time for the patient“, notes Steeve Chantrel, one of the three co-founders of medtech, whose ambition is to provide “a solution dedicated to intracranial operations as easy to use as a medical syringe“.

Remove the constraints

Accompanied by the MonacoTech incubator since the beginning of 2022, Infineis therefore designs personalized stereotactic medical devices which aim to drastically reduce the constraints linked to this type of intervention and therefore to simplify the patient journey within the hospital. hospital. “Our devices make it possible to guide the surgical gesture according to a rectilinear trajectory established on the standard preoperative imagery by the practitioner to reach with sub-millimeter precision the targeted anatomical zone. Less invasive, they are installed and operational in just a few seconds and do not require additional imaging, thus reducing operating times“, details the Franco-Canadian leader, specialized in health technologies. Single-use, they are designed and manufactured via the additive method according to the morphology of the patient and the trajectory (s) desired by the surgeon. “We stand at the crossroads of medical imaging, artificial intelligence and 3D printing“, he says. A patent is in progress.

The veterinary market first

Medtech intends to address different fields of application: profound deafness through the placement of cochlear implants, the treatment of dementia such as Parkinson’s disease for which the use of electrical stimulation devices supplants or supplements drug treatment, or even human and animal cerebral oncology. It is moreover in the veterinary field that the first tests are now being carried out with the aim of initiating the commercial phase of the devices on this market this autumn. “The veterinary world is doubly interesting for us. This is an unopened market that lacks the tools for this very expensive type of surgery despite strong demand from both practitioners and pet owners. Veterinary oncology is a promising market with double-digit growth over the next five years“Another advantage, the ongoing trials on cadaveric specimens, tomorrow on living specimens, will validate the solution and will serve as a prerequisite for the human clinical studies that the company wishes to begin in 2023. The young shoot is for this engaged in a fundraising process, it estimates the need to carry out the project on the human medical aspect between 2 and 2.5 million euros.

Different business models are considered. If the company intends to keep control of the process by manufacturing and delivering the device on demand, it plans to develop the model for international use. Because, explains Steve Chantrel, “one of the challenges behind all this is also to reduce medical deserts and give emerging countries access to this type of complex surgery“.